InvestorsObserver
×
News Home

Do Analysts Expect Evelo Biosciences Inc (EVLO) Stock to Rise After It Is Lower By -27.63% in a Month?

Monday, November 20, 2023 12:50 PM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Expect Evelo Biosciences Inc (EVLO) Stock to Rise After It Is Lower By -27.63% in a Month?

Wall Street is positive on Evelo Biosciences Inc (EVLO). On average, analysts give Evelo Biosciences Inc a Hold rating. The average price target is $10, which means analysts expect the stock to increase by 1718.18% over the next twelve months. That average ranking earns Evelo Biosciences Inc an Analyst Rating of 5, which is better than 5% of stocks based on data compiled by InvestorsObserver.

Overall Score - 3
Wall Street analysts are rating EVLO a Hold today. Find out what this means to you and get the rest of the rankings on EVLO!

Why are Analyst Ratings Important?

A company's financial statements are a significant factor weighted by experts when analyzing a company's health. Beyond just the numbers, analysts follow specific industries closely and are able to gain a detailed understanding of how a storm in one part of the world can shutdown supply chains leading to a change in consumption across the globe. This knowledge allows investors to respond to potential changes in the market before they are revealed in a quarterly annoucement. InvestorsObserver averages the ratings across all these analysts and percentile ranks those averages. This allows you to compare stocks in greater detail than the usual five-tiered system used amongst the majority of investors.

What's Happening With Evelo Biosciences Inc Stock Today?

Evelo Biosciences Inc (EVLO) stock is trading at $0.55 as of 12:29 PM on Monday, Nov 20, an increase of $0.06, or 11.98% from the previous closing price of $0.49. The stock has traded between $0.47 and $0.60 so far today. Volume today is low. So far 646,866 shares have traded compared to average volume of 1,189,354 shares. Click Here to get the full Stock Report for Evelo Biosciences Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App